An Open-Label, Rollover Platform Study for Continued Study Treatment and Ongoing Safety Monitoring
PLATFORMPACAN1001
Phase 1 other active
Quick answer
An Open-Label, Rollover Platform Study for Continued Study Treatment and Ongoing Safety Monitoring for Non-Hodgkin lymphoma and chronic lymphocytic leukemia is a Phase 1 program (other) at Janssen-Cilag International N.V. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Janssen-Cilag International N.V.
- Indication
- Non-Hodgkin lymphoma and chronic lymphocytic leukemia
- Phase
- Phase 1
- Modality
- other
- Status
- active